BELIEF: common adverse events reported in the safety population (1/3)¹

Data are n (%). Adverse events reported by 15% or more patients for grades 1–2, 2% or more patients for grade 3, and all adverse events for grades 4 and 5

Reference

Rosell R, et al. Lancet Respir Med 2017; 435–44

BELIEF: common adverse events reported in the safety population (2/3)¹

Data are n (%). Adverse events reported by 15% or more patients for grades 1–2, 2% or more patients for grade 3, and all adverse events for grades 4 and 5

Reference

Rosell R, et al. Lancet Respir Med 2017; 435–44

BELIEF: common adverse events reported in the safety population (3/3)¹

Data are n (%). Adverse events reported by 15% or more patients for grades 1–2, 2% or more patients for grade 3, and all adverse events for grades 4 and 5

Reference

Rosell R, et al. Lancet Respir Med 2017; 435–44

BELIEF: common adverse events reported in the safety population (1/3)1

BELIEF: common adverse events reported in the safety population (2/3)1

BELIEF: common adverse events reported in the safety population (3/3)1

BELIEF: common adverse events reported in the safety population (1/3)¹

BELIEF: common adverse events reported in the safety population (2/3)¹

BELIEF: common adverse events reported in the safety population (3/3)¹